Palvella Therapeutics
PVLA
65 hedge funds and large institutions have $40.1M invested in Palvella Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 13 increasing their positions, 21 reducing their positions, and 7 closing their positions.
600% more call options, than puts
Call options by funds: $126K | Put options by funds: $18K
3.4% less ownership
Funds ownership: 50.29% → 46.89% (-3.4%)
4% less funds holding
Funds holding: 68 → 65 (-3)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
38% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 21
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
70% less capital inflows, than outflows
Capital inflows: $2.21M | Capital outflows: $7.34M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$483K |
| 2 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$470K |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$385K |
| 4 |
Renaissance Technologies
New York
|
+$243K |
| 5 |
Platinum Investment Management
Sydney Australia 2000,
Australia
|
+$196K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2.6M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$1.93M |
| 3 |
Great Point Partners
Greenwich,
Connecticut
|
-$882K |
| 4 |
Citigroup
New York
|
-$556K |
| 5 |
XTX Topco
George Town,
Cayman Islands
|
-$186K |
PVLA Hedge Fund Activity: Q3 2022 in Review
65 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2022, worth a combined $40.1M — down 43% from $71M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PVLA and 5 opened new positions — a net loss of 2 holders — while 21 trimmed existing stakes and 13 added.
The largest buyer was Aquilo Capital Management, adding an estimated $483K. The largest seller was Bank of Montreal, exiting entirely with an estimated $2.6M sold.
- 65 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2022, down from 68 in Q2 2022.
- Funds reported $40.1M of Palvella Therapeutics stock for Q3 2022, down 43% quarter-over-quarter.
- 5 funds opened new Palvella Therapeutics positions in Q3 2022 and 7 closed out, a net change of -2 holders.
- The largest Palvella Therapeutics buyer in Q3 2022 was Aquilo Capital Management, an estimated $483K added.
- The largest Palvella Therapeutics seller in Q3 2022 was Bank of Montreal, an estimated $2.6M sold.
Based on aggregated 13F filings for Q3 2022.